Back to top
more

Emergent Biosolutions (EBS)

(Real Time Quote from BATS)

$14.15 USD

14.15
961,268

+0.34 (2.46%)

Updated Jul 25, 2024 10:37 AM ET

Zacks Rank:

This is our short term rating system that serves as a timeliness indicator for stocks over the next 1 to 3 months. How good is it? See rankings and related performance below.

Zacks Rank Definition Annualized Return
1Strong Buy24.15%
2Buy17.88%
3Hold9.47%
4Sell5.14%
5Strong Sell2.57%
S&P50011.11%

Zacks Rank Education - Learn about the Zacks Rank

Zacks Rank Home - Zacks Rank resources in one place

Zacks Premium - The only way to fully access the Zacks Rank

3-Hold of 5     3    

Style Scores:

The Style Scores are a complementary set of indicators to use alongside the Zacks Rank. It allows the user to better focus on the stocks that are the best fit for his or her personal trading style.

The scores are based on the trading styles of Value, Growth, and Momentum. There's also a VGM Score ('V' for Value, 'G' for Growth and 'M' for Momentum), which combines the weighted average of the individual style scores into one score.

Value Score A
Growth Score A
Momentum Score A
VGM Score A

Within each Score, stocks are graded into five groups: A, B, C, D and F. As you might remember from your school days, an A, is better than a B; a B is better than a C; a C is better than a D; and a D is better than an F.

As an investor, you want to buy stocks with the highest probability of success. That means you want to buy stocks with a Zacks Rank #1 or #2, Strong Buy or Buy, which also has a Score of an A or a B in your personal trading style.

Zacks Style Scores Education - Learn more about the Zacks Style Scores

C Value B Growth D Momentum C VGM

Industry Rank:

The Zacks Industry Rank assigns a rating to each of the 265 X (Expanded) Industries based on their average Zacks Rank.

An industry with a larger percentage of Zacks Rank #1's and #2's will have a better average Zacks Rank than one with a larger percentage of Zacks Rank #4's and #5's.

The industry with the best average Zacks Rank would be considered the top industry (1 out of 265), which would place it in the top 1% of Zacks Ranked Industries. The industry with the worst average Zacks Rank (265 out of 265) would place in the bottom 1%.

Zacks Rank Education -- Learn more about the Zacks Rank
Zacks Industry Rank Education -- Learn more about the Zacks Industry Rank

Top 33% (83 out of 250)

Industry: Medical - Biomedical and Genetics

Zacks Premium FeatureView All Zacks #1 Ranked Stocks

Better trading starts here.

Zacks News

Emergent Biosolutions (EBS) Stock Sinks As Market Gains: What You Should Know

by Zacks Equity Research

Emergent Biosolutions (EBS) closed the most recent trading day at $90.77, moving -0.55% from the previous trading session.

Emergent Biosolutions (EBS) Earnings Expected to Grow: Should You Buy?

by Zacks Equity Research

Emergent Biosolutions (EBS) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

Alexion (ALXN) Beats on Q3 Earnings & Sales, Ups '20 Guidance

by Zacks Equity Research

Alexion (ALXN) beats earnings and sales estimates in the third quarter of 2020.

Dr. Reddy's (RDY) Q2 Earnings Decline Y/Y, Sales Increase

by Zacks Equity Research

Dr. Reddy's (RDY) earnings decline year over year while sales increase in second-quarter fiscal 2021.

Ultragenyx (RARE) Loss Narrows Y/Y, Revenues Beat Estimates

by Zacks Equity Research

Ultragenyx (RARE) reports a narrower loss year over year and sales beat estimates in the third quarter of 2020.

Emergent Biosolutions (EBS) Stock Sinks As Market Gains: What You Should Know

by Zacks Equity Research

Emergent Biosolutions (EBS) closed the most recent trading day at $96.11, moving -1.58% from the previous trading session.

Has Emergent Biosolutions (EBS) Outpaced Other Medical Stocks This Year?

by Zacks Equity Research

Is (EBS) Outperforming Other Medical Stocks This Year?

Prothena (PRTA) to Advance Parkinson's Disease Drug to Phase II

by Zacks Equity Research

Prothena (PRTA) and partner Roche (RHHBY) plan to advance prasinezumab into a phase IIb study in patients with early Parkinson's disease.

Aptose (APTO) Initiates Phase I a/b Study in Leukemia Patients

by Zacks Equity Research

Aptose (APTO) doses first patient with acute myeloid leukemia in a phase I a/b study with CG-806, with a starting dose of 450 mg.

Regeneron's (REGN) Dupixent Gets Positive CHMP Opinion for Dermatitis

by Zacks Equity Research

Regeneron (REGN) gets positive CHMP opinion for Dupixent, recommending extending the approval in the European Union to include children aged 6 to 11 years with severe atopic dermatitis.

ASLAN Pharmaceuticals (ASLN) in Focus: Stock Moves 7% Higher

by Zacks Equity Research

ASLAN Pharmaceuticals (ASLN) saw a big move last session, as its shares jumped more than 7% on the day, amid huge volumes.

Alnylam (ALNY) Gets Positive CHMP Opinion for Lumasiran

by Zacks Equity Research

Alnylam (ALNY) gets positive opinion from the CHMP for lumasiran for the treatment of primary hyperoxaluria type 1.

Armata's AP-PA02 Gets IND Clearance by FDA to Initiate Study

by Zacks Equity Research

Armata's (ARMP) AP-PA02 IND application gets clearance from the FDA to initiate a phase Ib/IIa study for the treatment of Pseudomonas aeruginosa infections.

Anavex (AVXL) in Focus: Stock Moves 9.5% Higher

by Zacks Equity Research

Anavex (AVXL) saw a big move last session, as its shares jumped nearly 10% on the day, amid huge volumes.

Emergent Biosolutions (EBS) Gains As Market Dips: What You Should Know

by Zacks Equity Research

In the latest trading session, Emergent Biosolutions (EBS) closed at $99.55, marking a +1.86% move from the previous day.

3 Reasons Growth Investors Will Love Emergent Biosolutions (EBS)

by Zacks Equity Research

Emergent Biosolutions (EBS) could produce exceptional returns because of its solid growth attributes.

Bayer's Aliqopa Meets Primary Endpoint in Lymphoma Study

by Zacks Equity Research

Bayer's (BAYRY) Aliqopa combined with Rituxan met the primary endpoint of significantly prolonging PFS in a phase III study in patients with relapsed indolent non-Hodgkin's lymphoma.

Vertex to End Phase II Study on AAT Deficiency Candidate

by Zacks Equity Research

Vertex (VRTX) to discontinue phase II study on VX-814 based on the liver enzyme elevations observed and the determination that it would be difficult to safely achieve targeted exposure levels.

AnaptysBio Shares Up on Positive Top-Line Psoriasis Data

by Zacks Equity Research

AnaptysBio (ANAB) reports positive top-line data from an interim analysis of its phase II GALLOP study on imsidolimab for the treatment of moderate-to-severe generalized pustular psoriasis.

Immunomedics' Trodelvy Gets Orphan Drug Tag for Glioblastoma

by Zacks Equity Research

Immunomedics' (IMMU) lead product candidate, Trodelvy, gets FDA orphan drug status for the treatment of adult and pediatric patients with glioblastoma.

Alexion's Ultomiris Gets FDA Approval for New Formulation

by Zacks Equity Research

Alexion (ALXN) gets FDA approval for Ultomiris 100 mg/mL, a new advanced formulation for the treatment of adults with paroxysmal nocturnal hemoglobinuria and atypical hemolytic uremic syndrome.

The Zacks Analyst Blog Highlights: Emergent BioSolutions, Vertex Pharmaceuticals, Editas Medicine, Cellectis and Thermo Fisher

by Zacks Equity Research

The Zacks Analyst Blog Highlights: Emergent BioSolutions, Vertex Pharmaceuticals, Editas Medicine, Cellectis and Thermo Fisher

Aileron Therapeutics (ALRN) in Focus: Stock Moves 6.5% Higher

by Zacks Equity Research

Aileron Therapeutics (ALRN) saw a big move last session, as its shares jumped nearly 7% on the day, amid huge volumes.

Booming Gene Editing Market to Pep Up These 5 Biotech Stocks

by Zacks Equity Research

Advancements in gene editing have boosted the biotech space, putting the spotlight on five stocks that can make the most.

SpringWorks Therapeutics (SWTX) Surges: Stock Moves 9.6% Higher

by Zacks Equity Research

SpringWorks Therapeutics (SWTX) saw a big move last session, as its shares jumped nearly 10% on the day, amid huge volumes.